AS703569 Phase I in Patients With Solid Tumours

NCT ID: NCT00391521

Last Updated: 2014-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 104 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2010-06-30

Brief Summary

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Conditions

Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Regimen 1

Group Type: ACTIVE_COMPARATOR

AS703569

Intervention Type: DRUG

Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle

2

Regimen 2

Group Type: ACTIVE_COMPARATOR

AS703569

Intervention Type: DRUG

Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle

3

Regimen 3

Group Type: ACTIVE_COMPARATOR

AS703569

Intervention Type: DRUG

Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle

Interventions

AS703569

Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle

Intervention Type: DRUG

AS703569

Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle

Intervention Type: DRUG

AS703569

Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle

Intervention Type: DRUG

Other Intervention Names

MSC1992371A; Aurora kinase inhibitor; MSC1992371A; Aurora kinase inhibitor; MSC1992371A; Aurora kinase inhibitor

Eligibility Criteria

Inclusion Criteria

1. Histopathologically confirmed locally advanced or metastatic solid tumour that is either refractory after standard of care therapy for the disease or for which standard of care therapy is not reliably effective or has a cancer for which no standard therapy exists

2. Age greater than or equal to 18 years

3. Has read and understands the informed consent form and is willing and able to give informed consent, and subject authorization under Health Insurance Portability and Accountability Act (HIPAA). Fully understands requirements of the study and willing to comply with all study visits and assessments

4. Subjects and their partners must be willing to avoid pregnancy during the study and until 1 month after the last study drug administration. Males with female partners of childbearing potential and female subjects of childbearing potential must therefore be willing to use adequate contraception such as, intra uterine device, diaphragm, or condom, for the duration of the study. For the purposes of this study, childbearing potential is defined as: "All female subjects unless they are post- menopausal for at least two years, are surgically sterile or sexually inactive"

5. Negative serum pregnancy test at the screening visit for women of childbearing potential

Exclusion Criteria

1. Bone marrow impairment as evidenced by Hb < 9.0 g/dl, ANC < 1.5x 109/L, platelets < 75 x 109/L. Subjects may be transfused.

2. Renal impairment as evidenced by serum creatinine > 1.5 x ULN (upper limit of normal), and/or calculated creatinine clearance < 60 ml/min

3. Liver function abnormality as defined by total bilirubin > 1.5 ULN, or AST or ALT > 2.5x ULN at screening; for subjects with liver involvement AST or ALT > 5x ULN at screening

4. INR (blood coagulation) > 1.5 x ULN for subjects not on therapeutic doses of coumadin

5. History of CNS metastases, unless subject has been previously treated for CNS metastases, is stable by CT scan without evidence of cerebral edema, and has no requirements for corticosteroids or anticonvulsants

6. History of difficulty swallowing, malabsorption or other chronic gastro- intestinal disease or conditions that may hamper compliance and/or absorption of the tested product

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2

8. Known HIV, hepatitis C, or hepatitis B positivity

9. Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy or surgical intervention within 28 Days of Day 1 of study drug treatment (6 weeks for nitrosureas or mitomycin C), and must have fully recovered

10. Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation

11. Has received any investigational agent within 28 days of Day 1

12. Has history of any other significant medical disease or intervention including major gastric or small bowel surgery or has a psychiatric condition that might impair the subjects well-being or preclude full participation in the study

13. Is a pregnant or nursing female

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

EMD Serono

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Narmyn Rejeb, MD

Role: STUDY_DIRECTOR

Merck Serono S.A., Geneva

Locations

EMD Serono Medical Information Office

Rockland, Massachusetts, United States

Countries

United States

References

Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6.

Reference Type: RESULT

PMID: 23832397 (View on PubMed)

Other Identifiers

26865

Identifier Type: -

Identifier Source: org_study_id